Kornimate/medical-research-clean huggingface dataset:
safety and immunogenicity of sars-cov-2 vaccine in patients with rheumatic diseases

Conditions: Rheumatic Disease

Summary: the purpose of this study was to preliminarily evaluate the immunogenicity of sars-cov-2 vaccine in patients with rheumatic diseases. the clinical information collection and blood sample testing of 100 healthy people and 200 patients with rheumatic diseases will be completed in yunnan traditional chinese medicine hospital. research methods and procedures: clinical information collection and blood sample detection were carried out in healthy people and patients with rheumatic diseases, including systemic lupus erythematosus (sle), antiphospholipid syndrome (aps), rheumatoid arthritis (ra), sjogren's syndrome (ss), systemic sclerosis (ssc), idiopathic inflammatory myopathy (iim), systemic vasculitis and spinal arthritis

rheumatic diseases (rds) are a large class of systemic diseases caused by genetic background, environment and physics, infection, metabolism, endocrine, immune response and other reasons, mainly involving joints and surrounding tissues. the diseases covered include systemic lupus erythematosus (sle), antiphospholipid syndrome (aps), rheumatoid arthritis (ra) sjogren's syndrome (ss), systemic sclerosis (ssc), idiopathic inflammatory myopathy (iim), systemic vasculitis, spinal arthritis, etc. patients with rheumatic diseases have an increased risk of infection due to autoimmune dysfunction and long-term use of hormones and immunosuppressants. the incidence rate of coronary heart disease (covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (severe acute respiratory syndrome coronavirus 2, sars-cov-2) in 2019 has resulted in high incidence and mortality worldwide. although the epidemic prevention measures such as keeping distance and quarantine isolation have effectively improved and limited the epidemic scope and the number of infected people, the groups with low immunity are still the susceptible groups of sars-cov-2. vaccination is very important to suppress the epidemic and reduce the overall mortality. it can protect people from sars-cov-2 infection and the deterioration of covid-192, and has good safety. however, there are not enough reports on the safety and immunogenicity of sars-cov-2 vaccine in patients with rheumatic diseases. studies have reported that the immunogenicity of sars-cov-2 vaccine is reduced in immunocompromised patients, including the use of immunosuppressive drugs.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of rheumatic diseases in western medicine; * 18-70 years old, male or female; * the patient voluntarily participated in this clinical study, has been informed of relevant matters, and signed the informed consent form exclusion criteria: it does not meet the diagnostic criteria of rheumatic diseases in western medicine
pediatric hepatic tumors

Conditions: Liver Tumor

Summary: centralized biological collection of multicentric origin, retrospective and prospective of biological samples (tissues and fluids) taken within the framework of the diagnostic and therapeutic management of children and adolescents with liver tumor, and supported in the centers of french society for childhood cancers (sfce) with associated clinical database.


Eligibility criteria:
inclusion criteria: 1. - for inclusion in the clinical database: * children and adolescents (≤18 years at diagnosis) suffering from a primary liver tumor diagnosed after 01/01/1990 and treated in france * informed consent to the computerization of data signed by the patient or by parents or legal representatives if he is a minor. 2. - for inclusion in the biological collection (crb paris sud): * additional criteria: * availability of biological samples (tumor tissue, healthy tissue, plasma and / or serum). * informed consent to the use of biological remains signed by the patient or by parents or legal representatives if he is a minor. 3. - for the inclusion of deceased patients: * obtaining consent or failing this, seeking non-opposition to the computerization of data (for inclusion in the database) and the use of biological remains (for inclusion in the biological collection) of the patient or both parents or the legal guardian if he is a minor. exclusion criteria: * none
comparison of capsular stretching and passive joint mobilization in idiopathic adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the aim of this research is to determine the effects of capsular stretching versus passive joint mobilization on pain, range of motion and quality of life in patients with idiopathic adhesive capsulitis.

in reference study, patients with adhesive capsulitis were given the option to examine the immediate effects of posterior capsule stretching and scapular mobilization. they came to the conclusion that extending the posterior capsule improved shoulder range of motion. current study will assess all shoulder movements and also showing effect on quality of life of patients with adhesive capsulitis.

Eligibility criteria:
inclusion criteria: both genders * age : 30-50 years * pain and restricted movements of shoulder. * patient with adhesive capsulitis of stage 2 exclusion criteria: * patient with any intrinsic etiology such as haemarthrosis, rheumatoid arthritis ,infection or gout * patient with any severe trauma, shoulder dislocation, subluxation or ligament injury of the shoulder * fractures of the shoulder * peripheral neurological involvement in the upper extremity.

Keywords: range of motion shoulder pain
accuracy and acceptability of self-diagnostic methods for vaginitis in adolescent females

Conditions: Trichomonas Vaginalis

Summary: symptoms of vaginitis are common among adolescent females, although studies have shown that neither experienced clinicians nor patients can accurately diagnose the cause of vaginitis based on symptoms alone. the purpose of this study is to investigate the accuracy and acceptability of self-diagnostic methods for vaginitis in adolescent females.

vaginal symptoms are common among adolescent females. vaginal symptoms can result from alterations in the normal flora such as candidiasis or bacterial vaginosis (bv), or from sexually transmitted infections (stis) such as trichomonas vaginalis (tv). however, studies have shown that neither experienced clinicians or patients can accurately diagnose the etiology of vaginitis based on symptoms alone, and the standard evaluation (pelvic examination and wet mount) has limitations. as an alternative to the standard evaluation, there are several objective, point-of-care tests that can be performed on vaginal secretions, which could be useful in discriminating between the various causes of vaginitis. these include a rapid test for trichomonas vaginalis, a rapid test for bacterial vaginosis, and the vaginal ph and amine test. the aims of this study are to explore the feasibility, accuracy (e.g., correlation, sensitivity, specificity) and acceptability of self-performed versus clinician-performed tests for vaginitis in adolescent females. approximately 300 adolescent females will undergo self- and clinician-testing for both sti and non-sti vaginitis. subjects will be randomized into two groups. group 1 will perform self-testing for the first half of the study before receiving clinician-testing for the remainder of the study. group 2 participants will receive clinician-testing for the first half of the study before performing self-testing for the remainder of the study. all participants will have a discussion with the clinician to compare the results of self-performed tests with the results obtained by the clinician. investigators will assess their acceptance of self- and clinician-testing before testing, after testing, and after the discussion with the clinician.

Eligibility criteria:
inclusion criteria: * sexual intercourse in the last 6 months * agree to perform self-testing * agree to pelvic examination exclusion criteria: * have taken antibiotics used to treat vaginal infections in the 2 weeks prior to study entry or have used vaginal creams or medications in the 2 weeks prior to study entry

Keywords: sexually transmitted infections acceptability adolescent vaginitis
a trial of rsl versus wl for malignant breast disease

Conditions: Breast- Female

Summary: the purpose of this randomized trial is to determine the superiority of utilizing radioactive seed localization (rsl) over wire-guided localization (wl) for palpable or non-palpable malignant lesions in patients undergoing breast conservation surgery (bcs).

consented and eligible subjects will be randomized to either radioactive seed localization or wire localization and stratified by surgeon and invasive versus dcis prior to localization. subjects on both arms will undergo breast conservation surgery including surgical specimen removal. specimens will be grossed according to standard of care procedures. localization, breast conservation surgery, and post-operative appointments will follow standard of care guidelines. surveys will be administered according to the study calendar to the radiologist, surgeon, pathologist, and subject for data collection.

Eligibility criteria:
inclusion criteria: * female * 20 to 99 years of age * breast lesion necessitating image-guided excision * unifocal disease * breast-conservation candidate * biopsy-proven malignant breast lesion including by not limited to invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ * signed written informed consent document by the subject and/or a lar exclusion criteria: * male * multifocal or multicentric disease * receiving neoadjuvant chemotherapy * pregnant or breastfeeding * locally advanced disease * breast conservation contraindication such as inability to receive whole breast radiation therapy, inability to tolerate localization procedure, inability to lay flat or prone for radiation, and undesirable tumor to breast ratio * prior breast cancer on ipsilateral side * unable or unwilling to adhere to post-localization instructions (e.g. timely seed removal)
getna2 neoadj. tax+femara vs femara in g i/ii breast cancer

Conditions: Breast Neoplasms

Summary: primarily to evaluate the rates of clinical and radiological response in the 2 groups. secondarily rate of histological response.


Eligibility criteria:
inclusion criteria: * female patients with breast cancer histologically proven by microbiopsy (14g or 16g) enabling confirmation of the diagnosis, and evaluation of the histological prognostic grade, hormonal receptors and her2 status. * tumor t2 or t3, non-metastasized, non-inflammatory, unilateral * clinically or radiologically measurable lesion greater than 2 cm (ultrasound and/or mammogram) * receptors re+ and/or rp+ (positive status determined according to the criteria of the investigating centers) * her 2 / neu status of 0, 1+ or 2+ in immunohistochemistry * histological grade i or ii * menopausal patients aged greater than or equal to 60 years * patients with ecog ps greater than or equal to 2 * satisfactory hematological, hepatic and renal functions: * hemoglobin greater than or equal to 10 g/dl * platelet count greater than or equal to 100x109/l * polynuclear neutrophil count greater than 1.5x109/l * creatinine less than or equal to ≤ 1.5 uln * ast/alt less than or equal to 1.5 uln * alkaline phosphatases less than or equal to 2.5 uln * patients able to be followed throughout the study * patient's consent obtained. exclusion criteria: * inflammatory or t4 breast cancer * t1 tumor * patients whose tumor is deemed by the doctor to be difficult to evaluate * tumor that is metastatic from the outset (m1) or locally advanced and inoperable from the outset * re and rp receptors negative or unknown * her 2/neu positive at 3 + * non-menopausal patients * surgical biopsy and/or ganglion dissection before neoadjuvant treatment * significant poorly controlled cardiac disorders, such as unstable angina pectoris, poorly controlled heart failure, arrhythmia requiring treatment, or myocardial infarction within the last 3 months * cardiovascular, hepatic, neurological or endocrine disease, or other major systemic disease that makes it difficult to conduct the protocol or to interpret the results * previous history of cancer that occurred within the last 10 years, with the exception of cervical cancers and basocellular skin cancers that were properly treated * allergy to polysorbate 80 * hypersensitivity to docetaxel * participation in another clinical trial with one of the study medicinal products during the 30 days prior to entry in the study * patients who are unable to undergo medical monitoring for geographical, social or psychological reasons
escitalopram as a treatment for pain in polyneuropathy

Conditions: Pain; Polyneuropathies

Summary: many people with polyneuropathy suffer from pain which is difficult to treat. escitalopram is a relatively new drug used in the treatment of depression. escitalopram's action mechanism on the brain suggests that escitalopram also may have an effect on neuropathic pain. this study will test the efficacy of escitalopram in patients with painful polyneuropathy.

tricyclic antidepressants appear to be the most efficacious treatment of painful polyneuropathy. however, these drugs are contraindicated in some patients and a substantial number of patients decline treatment due to side-effects. therefore, effective drugs that are better tolerated are needed. clinical and basic research has demonstrated that drugs with serotonergic action can alleviate neuropathic pain. escitalopram increases serotonin concentration in the central nervous system, suggesting that it might be a potential alternative to current treatments of neuropathic pain. the aim of this study is to test if escitalopram would relieve painful polyneuropathy. comparisons: treatment with 20 mg escitalopram daily will be compared in a cross-over design with placebo. each treatment period will last 6 weeks. during the last week of each treatment period, the dose will be tapered.

Eligibility criteria:
inclusion criteria: * median total pain score at baseline week \>=4 on a 10 point numerical rating scale * characteristic symptoms of polyneuropathy within at least 6 months * diagnosis confirmed by physical examination, neurophysiologic exam. and/or quantitative sensory testing * pain at least 4 of 7 days * fertile women are using anticonceptive exclusion criteria: * other cause to pain than polyneuropathy * former allergic reactions on escitalopram * known adverse events on escitalopram * pregnancy or nursing * critical disease (terminal cancer, cardial incompensation or critical renal or lung disease) * treatment with monoamine oxidase inhibitors between the trial or 2 weeks before or after treatment with other antidepressants, antiepileptic agents or opioids

Keywords: polyneuropathies pain drug effects escitalopram serotonin uptake inhibitors
therapists' preferences for client characteristics and their influence on the therapeutic alliance

Conditions: Diagnosis, Psychiatric; Outpatient Followup of Psychiatric Problem

Summary: the research will examine psychotherapists' preferences for theoretical client characteristics, such as age, gender, personality characteristics and symptoms. the research will also examine the preferences' influence on the therapeutic alliance, from the therapist's and the client's point of view.


Eligibility criteria:
inclusion criteria: * outpatients over the age of 18, * hebrew speakers, * not in a psychotic state. exclusion criteria: * psychotic state, * under the age of 18, * not qualified to answer the questions, * don't speak any hebrew at all.

Keywords: psychotherapy preferences
randomized ph 2 trial of paclitaxel/carboplatin /bevacizumab + pf-3512676 and p/c/b alone in advanced nonsquamous nsclc

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: to assess the efficacy and safety of pf-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer

pf-3512676 dosing was stopped 21 june 2007 when pfizer decided to stop the administration of pf-3512676 in all trials which combined pf-3512676 with cytotoxic chemotherapy. the decision was made subsequent to dsmc recommendation to close two phase iii randomized trials in non-small cell lung cancer which also combined pf-3512676 with cytotoxic chemotherapy, citing lack of efficacy concerns as the primary reason with safety issues (sepsis, thrombocytopenia) also contributing to the decision. subjects were allowed to complete standard of care treatment/survival follow-up. data collection was completed on 22 may 2008.

Eligibility criteria:
inclusion criteria: * advanced stage iiib with pleural effusion or stage iv nonsquamous non-small cell lung cancer * ecog performance status 0-1 * measurable disease per recist criteria exclusion criteria: * squamous cell, small cell, or carcinoid lung cancer * cns metastasis * pre-existing autoimmune or antibody mediated disease * prior systemic treatment for nsclc with chemo, immunotherapy, biologics, or investigation drugs

Keywords: advanced carcinoma, non-small cell lung, phase ii, paclitaxel, taxol, carboplatin, paraplatin, bevacizumab, avastin, pf-3512676, immunotherapy, immunomodulator
echinacea purpurea and osteopathy in children with recurrent otitis media

Conditions: Otitis Media

Summary: this study was designed to evaluate the efficacy of the herb echinacea purpurea and of cranial osteopathic manipulative treatment to prevent otitis media (middle ear infections) in young children.

the use of complementary and alternative therapies by parents of young children remains common despite the lack of clinical trials demonstrating either the efficacy or safety of these treatments. two of the more common complementary therapies used in young children with a history of recurrent otitis media are preparations of the herb echinacea purpurea and cranial osteopathic manipulative treatment. this study represents one of the first double-blinded, placebo controlled trials of each approach in a population of young children who presented with three or more recent episodes of acute otitis media.

Eligibility criteria:
inclusion criteria: * 3 or more separate episodes of acute otitis media within a 6 month period, or * 4 episodes of acute otitis media in one year, exclusion criteria: * congenital malformations of the ears, nose, or throat * known or suspected allergy to echinacea * immune deficiency including hiv infection * tuberculosis * current use of prophylactic antibiotics * tympanostomy tubes in place * unwillingness of child to participate

Keywords: otitis media echinacea osteopathic medicine
structural mitral valve project

Conditions: Mitral Regurgitation

Summary: this is a prospective quality improvement (qi) study using the model for improvement framework. the objective of this study is to implement a structured, comprehensive, innovative, and sustainable approach to the management of patients with advanced mitral valve (mv) disease and heart failure (hf) in southeastern ontario and to improve healthcare delivery, patient care, and patient outcomes in the context of structural surgical and percutaneous mv interventions. this will be achieved through the strategic implementation, promotion, and evaluation of: i.the first local southeastern ontario structural mitral valve clinic using an interdisciplinary heart team (iht) at the kingston health sciences centre (khsc) and its integration with the khsc's existing heart failure clinic; ii.the first provincial structural mitral valve clinic electronic referral service on the ontario electronic services platform; and iii.the promotion of the above through targeted kt (knowledge transfer) outreach activities. patients for this study will be recruited through medical referral within the south eastern ontario, canada region.


Eligibility criteria:
inclusion criteria: all adults (≥18 years of age) patients with primary and secondary moderate to severe mr with hf (preserved or reduced ejection fraction with new york heart association (nyha) class \>ii), who have had at least one previous hospitalization for hr, require specialist advisement, and have provided signed informed consent. exclusion criteria: * those who are not eligible for either an mv surgical intervention or a tmvi procedure. * females of childbearing age who are not willing or unable to use a reliable method of birth control. * inpatient referrals.
right ventricular haemodynamic evaluation and response to treatment

Conditions: Right Ventricular Dysfunction

Summary: mono-center study to evaluate different multimodal functional parameter of the right ventricle in pah-patients

mono-center-study tu evaluate functional parameters in cardiac mri, conductance catheter (pressure-volume-loops), echocardiography and right heart catheter in pah patients and to compare different multimodal parameters

Eligibility criteria:
inclusion criteria: * ph nizza group 1 and patients without pulmonary hypertension after having the right heart catheter on clinical grounds * ability to sign informed consent * male and female between 18 to 85 years * haemodynamic criteria: * pulmonary vascular resistance (pvr) \> 240 dyn x sec x cm-5 * mean pulmonary artery pressure (mpap) ≥ 25 mmhg for pah patients * normal haemodynamic in controls * therapy-naive or at least since two months stabil therapy with approved drugs for pah (sildenafil, tadalafil, macitentan, ambrisentan, bosentan, iloprost, treprostinil, riociguat). exclusion criteria: * therapy with positive inotropic drugs (dobutamin etc.) * missing informed consent * pregnancy or lactation
effect of desmopressin on the nocturnal micturition frequency in patients with parkinson disease

Conditions: Parkinson Disease

Summary: this study will be conducted to study the effect of desmopressin on the nocturnal micturition frequency in patients with idiopathic parkinson syndrome.


Eligibility criteria:
inclusion criteria: * male patients with idiopathic parkinson syndrome * 18 to 85 years * nocturnal pollakisuria \> 2 mictions /night (documented in screening phase ) * na+ i.s \> 135 mmol/l * patient is able to understand all aspects and individual consequences of the clinical trial * an informed consent signed and dated by the patient is available prior to any study specific treatment * the study is consistent with the patients´ request for an appropriate treatment exclusion criteria: * intake of the following concomitant medication: carbamazepin, oxcarbazepine, diuretics (furosemide, torasemide), non steroidal antiphlogistics, loperamide, antidiuretic hormone analoga (besides study medication), drugs for treatment of bladder disfunction, in particular anticholinergics * central diabetes insipidus * known heart insufficiency (nyha stad. iii und iv) * clinical relevant kidney insufficiency * habitual and psychogenic polydipsia * hypersensitivity or allergy against the trial medication or any other ingredient of the trial medication * participation in another clinical trial during or within 6 months prior to this clinical trial * medical or psychological condition, which might endanger the proper conduction of the clinical trial * known drug or alcohol abuse

Keywords: nycturia parkinson syndrome desmopressin nocturnal polyuria in patients with parkinson syndrome